ABOUT HUGEL

New Hope, Better Life

History

PRESENT

  • 2023
    06
    Received IND approval for phase 3 clinical trial of ‘HG102’, a lidocaine-containing liquid botulinum toxin in Korea
  • 2022
    11
    Hugel included into the KOSDAQ Global Segment Received marketing approval for botulinum toxin 50/100units in Australia
    09
    Received marketing approval
    for botulinum toxin 50/100/200units in Indonesia Submitted IND for phase II clinical trial for ‘HG301’, a lipolysis injectable
    06
    Launched PCL absorbable thread, ‘Blue Rose Clair’ in Korea
    Received marketing approvals for botulinum toxin 50/100units in Canada
    05
    Completed phase I clinical trial for ‘HG102,’
    a lidocaine-containing liquid botulinum toxin in Korea
    04
    Change in major shareholder to Aphrodite Acquisition Holdings LLC
    Received marketing approval for hyaluronic acid filler in China
    01
    Launched ‘BYRYZN Skin booster HA’ in Korea Received recommendation for marketing approval of botulinum toxin 50units in Europe
  • 2021
    06
    Submitted BLA for botulinum toxin 50/100units in Canada and Australia
    03
    Submitted BLA for botulinum toxin 50/100units in the U.S.
    02
    Received marketing approval
    from China NMPA for botulinum toxin 50units
    01
    Received MFDS approval for botulinum toxin 300units Received IND approval for phase 1 clinical trial of ‘HG102’, a lidocaine-containing liquid botulinum toxin in Korea